Global stock

NASDAQUSD

Henry Schein Inc.

HSIC

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

60/ 100

Overall score·HSIC

Current price

84.96USD

23/10/2026

P/E, P/B

Valuation

Neutral

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Forward P/E 14,2 a P/S 0,71 působí příznivě, zatímco současné P/E 24,9 a EV/EBITDA 13,6 ukazují na méně jednoznačné ocenění. Růst zisku a tržeb je solidní, ale nízké marže a návratnost kapitálu jsou slabšími stránkami; cena je nad 50denním i 200denním průměrem, přestože za posledních 30 dní klesla.

§ Outlook vs S&P 500Next 12 months

Probably yes

Estimated chance of beating the index: about 56%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Metrics summary

A quick look at Henry Schein Inc. (HSIC) combining financial health, the short-term signal, valuation, DCF, management quality and operating metrics. It is analytical context, not a recommendation to buy or sell.

60/100

The overall score is based mainly on long-term fundamentals, complemented by the current signal and the available qualitative rating of the company.

57/100

Slightly positive signal based on current news, price action and the economy.

62/100

A lower score means the stock is expensive relative to the company's earnings and assets.

1% below fair value

An estimate of what the stock should be worth based on the company's future cash.

+7%

How fast the company's revenue grows year on year.

44/100

How much the company earns from each unit of revenue and from invested capital.

62/100

Debt level, share-price volatility and how resilient the company is in bad times.

65/100

AI estimate of management quality, execution and capital allocation.

72/100

AI estimate of the company's durable competitive advantage.

§ Financial results

Financial results·HSIC

mld. USD

RevenueEBITDANet incomeEBITDA margin

Margins and profitability·HSIC

Net marginEBITDA marginDashed = estimate

Net margin

+3.0 %

FY 2025 · reported

EBITDA margin

+7.3 %

FY 2026 · estimate

Net margin

+3.0 %

last 12 months

Operating margin

+5.8 %

last 12 months

ROE

+8.9 %

last 12 months

FY = fiscal year · TTM = trailing 12 months

§ Context and events

Management

Vedení zahrnuje Ronalda N. Southa, senior viceprezidenta a CFO, a Michaela Saula Ettingera, výkonného viceprezidenta a COO. Mark E. Mlotek je výkonným viceprezidentem a ředitelem pro strategii; Andrea Albertini vede globální distribuci a technologie. Firma kombinuje distribuci zdravotnického materiálu s technologiemi a službami pro ordinace.

Articles about Henry Schein Inc., in Czech (0)

No articles yet. New analyses are published daily.

§ Upcoming results

3 November 2026

in 7 days

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is Henry Schein Inc. (HSIC)?

Henry Schein Inc. (HSIC) is a global stock traded on NASDAQ. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the Henry Schein Inc. price today?

As of 23 October 2026, Henry Schein Inc. trades at about 84.96 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy Henry Schein Inc.?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does Henry Schein Inc. pay a dividend?

Henry Schein Inc. either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is Henry Schein Inc. a good investment in 2026?

Our AI signal currently rates Henry Schein Inc. as slightly positive (score 57/100). Financial health comes out at 60/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. The DCF model currently puts the price about 1 % below its model fair value. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy Henry Schein Inc.

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Slightly positive

Earnings in 7 days

On 3 November 2026 the company publishes its quarterly results. This period tends to bring large price moves.

News summary

Older news

Signal 19/10, 21:02

Henry Schein vykázal tržby 3,46 mld. USD, meziročně vyšší o 6,7 % a 2,6 % nad odhady; dopad podpoří další růst, ale zatím stagnující kurz jej omezuje.

Výsledky a silné provozní plnění mírně podporují výhled, avšak kurz za 7 dní téměř stagnuje a klesající trend s RSI 42 ukazují na slabší krátkodobé momentum.

Risks: Pokračující pokles při slabším výhledu tržeb či marží by oslabil pozitivní dopad výsledků.

More about the signal

Výsledky a silné provozní plnění mírně podporují výhled, avšak kurz za 7 dní téměř stagnuje a klesající trend s RSI 42 ukazují na slabší krátkodobé momentum.

Risks: Pokračující pokles při slabším výhledu tržeb či marží by oslabil pozitivní dopad výsledků.

Signal history· 2

18/1005:0150 · Neutral
Před výsledky Henry Schein se pozornost soustředí na nadcházející zveřejnění; případný dopad na výhled potvrdí až oznámené výsledky a komentář vedení.
12/1022:0250 · Neutral
Henry Schein oznámil jmenování Emmanuela Capraise finančním ředitelem; samotná personální změna může podpořit kontinuitu řízení, její dopad však závisí na realizaci firemních priorit a trhu ji může vyhodnotit jinak.

The full 90-day signal history is part of Premium.

Ask the AI

§ Model fair value (DCF)

Fairly valued1% below fair value

85.67

range 67.3 – 112.3

Current price

84.96 USD

23 Oct 26

PriceFair value range (DCF)UndervaluedOvervalued

What the calculation is based on

Model

85.67 USD

range 67.3 USD – 112.3 USD

: 5.0%
: 8.5%
: 4.50 USD

Růst 5 % p. a. je konzervativní předpoklad pro zavedeného distributora zdravotnického vybavení, s ohledem na růst tržeb a nejistotu, zda se růst EPS promítne do FCF. Diskontní sazba 8,5 % zohledňuje relativně nižší betu, ale také zadlužení a nízkou provozní marži.

DCF terms explained+

DCF (discounted cash flow) estimates how much cash the company will generate in the future and converts it into today's value per share.

Free cash flow (FCF) is the money left after running the business and investing. “12 m” means the last 12 months.

The discount rate expresses risk: the riskier the company, the higher the rate and the lower the fair value.

Fair value is a model estimate — not the market price and not an investment recommendation.

With Premium you can adjust growth, the discount rate and free cash flow, and the fair value recalculates live.

Adjust assumptions14 days free →

A model estimate, not an investment recommendation. Past performance does not guarantee future results.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 18 of 18

Valuation score

3/ 6

6/6 tests available

1. Below DCF fair value

0.8% below the DCF midpoint.

2. Well below DCF value

Discount = below the range or at least 15% below the midpoint.

3. Price vs. the last year

73% above the 1-year low (68.99 USD to 90.86 USD), based on stored daily prices.

4. P/E vs. similar companies

P/E 24.9 vs. median 26.7 (71 companies).

5. P/E relative to growth

PEG 1.7; a lower value means cheaper growth.

6. Analyst price target

14.0% vs. the current price, 15 analysts.

Price vs DCF

Current price

84.96 USD

Low 67.32 USDHigh 112.3 USD

Current priceDCF midpoint: 85.67 USD

Price vs analyst target

Current price

84.96 USD

Low 64.00 USDHigh 110.0 USD

Current priceAverage: 96.87 USD

DCF gap

within range

The price is within the model range of 67.32 USD to 112.3 USD.

Analyst target

+14.0%

Average target 96.87 USD vs. price 84.96 USD.

Analyst consensus

Target range

64.00 USD - 110.0 USD

Coverage

15 analysts

Analyst consensus

2.4 / 5

Changes 180 d

+1 / -0

EPS next year

11.3%

Revenue next year

4.1%

Valuation multiples

24.9

14.2

3.0

0.7

13.6

1.7

52-week range73% above the low

68.99 USD90.86 USD

17.0%

7.0%

3.0%

8.9%

Price vs 50D-2.6%

Price vs 200D5.2%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 23/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

good

Skóre odráží zkušené vedení a strategii rozšiřování nabídky akvizicemi a digitálními službami, vyvážené středním governance rizikem, zejména u dohledu představenstva.

strong

Rozsáhlá distribuční síť, dlouhodobé vztahy se zdravotnickými ordinacemi a doplňkové služby vytvářejí výhodu rozsahu a určité náklady na změnu dodavatele, konkurenční tlak však její sílu omezuje.

Information

Type: Global stock
Symbol: HSIC
Exchange: NASDAQ
Currency: USD
Sector: Healthcare
: 24.9x
: 9.7B USD
: 80.7 %
: 0.84

§ Risk profile

Rizikem je tlak na nízké distribuční marže, konkurence a případné výpadky či zdražení dodávek. Výsledky mohou ovlivnit také změny poptávky po stomatologických a ambulantních službách a pro českého investora výkyvy kurzu USD/CZK.

Ask the AI about Henry Schein Inc.All signals